Skip to content
DataLookout
Menu

REZILIENT3NCT05973773

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 16 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 45 words Show 4 more changesShow less
    • Trial sites reduced: 130 → 110 locations
    • Secondary endpoints: details revised at 3 of 11 entries
    • Publications: details revised at 1 of 1 entry
    • Study description expanded, about 2 words
  2. Notable Primary completion pushed from Oct 29, 2026 to May 27, 2027
    • Site details revised at 35 of 130 sites
    v17
  3. Minor Study sites: 128 to 130v16
  4. Notable Start date: Jun 30, 2023 to Dec 18, 2023
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 272 to confirmed 285
    • Study sites: 131 to 128
    v15
  5. Minor Primary completion date: Jul 27, 2026 to Oct 29, 2026
    • Study completion date: Aug 24, 2026 to May 27, 2027
    v14
Show 10 earlier versionsHide 10 earlier versions
  1. Minor Study sites: 114 to 131v13
  2. Minor Study sites: 103 to 114v12
  3. Minor Study sites: 92 to 103v11
  4. Minor Study sites: 87 to 92v10
  5. Minor Study sites: 83 to 87v9
  6. Minor Study sites: 82 to 83v8
  7. Notable Eligibility criteria expanded, about 244 wordsv5 Show 5 more changesShow less
    • Enrollment target: 312 to 272
    • Primary completion date: Jan 30, 2026 to Jul 27, 2026
    • Study completion date: May 21, 2026 to Aug 24, 2026
    • Study description expanded, about 27 words
    • Study title shortened, about 17 words
  8. Minor Study sites: 71 to 82v4
  9. Minor Study sites: 1 to 71v3
  10. Minor Primary completion date: Dec 30, 2026 to Jan 30, 2026
    • Study completion date: Apr 21, 2027 to May 21, 2026
    • Start date: Jun 26, 2023 to Jun 30, 2023
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Part A and B: The rate and severity of treatment emergent AEs
Timeframe: approximately 5 years
Part A and Part B: Progression-free survival (PFS) by blinded independent central review (BICR)
Timeframe: approximately 5 years
Part A: The rate and severity of DLTs according to the NCI-Common Terminology Criteria of Adverse Events (CTCAE) v5.0 during Cycle 1
Timeframe: approximately 5 years

Secondary (11)

Part A and Part B: Objective response rate (ORR)
Part A and Part B: Disease control rate (DCR)
Part A and Part B: Duration of response (DoR)
Part A and Part B: Intracranial (i) Overall Response Rate (iORR)
Part A and Part B: Intracranial duration of complete response (iDCR)
Show 6 moreShow less
Part A and Part B: Intracranial duration of Response (iDoR)
Part B: Overall survival (OS)
Pharmacokinetic (PK) parameter
European Quality of Life 5 Dimensions, 3 Level Version (EQ-5D-3L)
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30
Non-small Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ )

Arms and interventions

Part A (Safety Lead in)Experimental

Part A: Safety Lead-In Approximately 6-12 patients will receive zipalertinib administered at an initial dose of zipalertinib PO BID (Dose Level 1) in combination with pemetrexed and carboplatin or cisplatin on a 21-day cycle. Patients may continue to receive study treatment until documentation of progressive disease (PD) or until other withdrawal criteria are met, whichever comes first.

Part BExperimental

Enrollment into the Phase 3 portion of the study will begin following completion of Part A. Approximately 260 patients will be randomized on a 1:1 basis to receive pemetrexed and a platinum agent (either carboplatin or cisplatin) with or without zipalertinib on a 21-day cycle. Carboplatin or cisplatin will be administered for 4 cycles. Patients may continue to receive zipalertinib (experimental study arm) and pemetrexed (both study arms) until documentation of PD or until other withdrawal criteria are met, whichever comes first.

Drugs: TAS6417

Sites

110 sites in 22 countries

Japan 14, Italy 9, Spain 9, Turkey (Türkiye) 8, United States 8, South Korea 7, France 6, Mexico 6, Brazil 5, Singapore 5, Belgium 4, Canada 3, Germany 3, Israel 3, Netherlands 3, Philippines 3, Poland 3, Thailand 3, United Kingdom 3, Chile 2, Romania 2, Greece 1